Study ID: CTSU S1201

Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric, or Gastroesophageal Junction (GEJ) Cancer


The purpose of this study is to find out what effects (good or bad) a targeted therapy (treatment that is based on specific characteristics of each patient¿s tumor cells) approach has on participants and their cancer. Participants in this study have been diagnosed with either esophageal, gastric, or gastroesophageal junction cancer.

Bemidji Clinic, Fargo Region, Sioux Falls Region
Principal Investigator:
Miroslaw Mazurczak MD,Preston Steen, MD,Preston Steen, MD
Esophagus, GE Junction, Stomach
Phase II


Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list